Edwards has exercised its option to acquire Endotronix, enhancing its capabilities in the heart failure management space. Credit: Umaporn Kensila / Shutterstock.

Edwards Lifesciences has announced strategic acquisitions of JenaValve Technology and Endotronix to expand its structural heart portfolio.

These investments aim to address unmet patient needs and drive long-term growth within the structural heart sector.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The upfront purchase price for these investments totals nearly $1.2bn, with the finalisation of the deals contingent on regulatory approvals.

JenaValve Technology provides transcatheter treatment of aortic regurgitation (AR). The company’s Trilogy Heart Valve System is expected to receive approval from the US Food and Drug Administration in late 2025 to treat AR.

Edwards has also exercised its option to acquire Endotronix, enhancing its capabilities in the heart failure (HF) management space.

This acquisition is expected to expand Edwards’s structural heart portfolio into a new therapeutic area for addressing the needs of HF patients.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Edwards CEO Bernard Zovighian said: “These acquisitions expand our opportunities to address the unmet needs of aortic regurgitation and heart failure patients around the world.

“We are pleased to enter these structural heart therapeutic areas with innovation, world-class science and clinical evidence to provide access to life-saving technologies for patients around the world.”

These strategic moves are anticipated to boost Edwards’ position as a leader in structural heart innovation.

Furthermore, the company expects minimal revenue contribution from the acquisitions of JenaValve and Endotronix in 2025.

Last week, Edwards said it was exercising its option to acquire Israeli company Innovalve Bio Medical to advance its early-stage transcatheter mitral valve replacement (TMVR) business.

In an official filing with the US Securities and Exchange Commission, Edwards said it expects to pay around $300m in cash at the closing of the acquisition.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact